Stock Research: Sino Biopharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Sino Biopharmaceutical

HKG:1177 KYG8167W1380
35
  • Value
    60
  • Growth
    67
  • Safety
    Safety
    29
  • Combined
    49
  • Sentiment
    26
  • 360° View
    360° View
    35
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 35 (better than 35% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sino Biopharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Sino Biopharmaceutical. The consolidated Value Rank has an attractive rank of 60, which means that the share price of Sino Biopharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 60% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 67, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 26. Professional investors are more confident in 74% other stocks. Worryingly, the company has risky financing, with a Safety rank of 29. This means 71% of comparable companies have a safer financing structure than Sino Biopharmaceutical. ...read more

more
Index
Hang Seng
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
60 n/a n/a n/a
Growth
67 n/a n/a n/a
Safety
Safety
29 n/a n/a n/a
Sentiment
26 n/a n/a n/a
360° View
360° View
35 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
71 n/a n/a n/a
Opinions Change
12 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
15 n/a n/a n/a
Sentiment
26 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
60 n/a n/a n/a
Growth
67 n/a n/a n/a
Safety Safety
29 n/a n/a n/a
Combined
49 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
44 n/a n/a n/a
Price vs. Earnings (P/E)
40 n/a n/a n/a
Price vs. Book (P/B)
35 n/a n/a n/a
Dividend Yield
85 n/a n/a n/a
Value
60 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
72 n/a n/a n/a
Profit Growth
81 n/a n/a n/a
Capital Growth
1 n/a n/a n/a
Stock Returns
83 n/a n/a n/a
Growth
67 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
50 n/a n/a n/a
Refinancing
6 n/a n/a n/a
Liquidity
76 n/a n/a n/a
Safety Safety
29 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to Sino Biopharmaceutical and broaden your portfolio horizons.

Perusahaan Perkebunan London Sumatra Indonesia

JKT:LSIP
Country: Hong Kong
Industry: Agricultural Products
Size: Medium
Full Stock Analysis

Nippon Shinyaku

TYO:4516
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

CK Asset Holdings

HKG:1113
Country: Hong Kong
Industry: Real Estate Development
Size: X-Large
Full Stock Analysis

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a mixed bag with good value and high growth balanced by risky financing and negative sentiment. This is a risky stock that requires conviction; you should only consider it if you are willing to conduct further research into the underlying sentiment and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: